Gelteq Limited Ordinary Shares
GELS
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $8.3M
$0.90
▲ +0.76%
P/E
-7.20
Mkt Cap
$8.3M
52-Wk Range
$0.39–$2.01
52-Week Range
$0.39 - $2.01
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 42.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary gel-based delivery technology platform
- Versatile applications across multiple therapeutic and consumer segments
- White-label business model enabling rapid market penetration
- Early-mover advantage in gel delivery innovation
Bear Case
1 risk
- Low volatility (beta -0.4).
Growth
No forward estimates available
Increasing demand for alternative drug delivery systems in pharmaceutical industry
Value
Valuation data unavailable
Momentum
Hot
+87.5% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GELS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Most recent quarter reported revenue of $62.0K. Reported EPS of -$0.12.
Reported EPS · last 4Q
Q1 26
-$0.12
Q4 24
$0.00
Q3 24
$0.00
Q4 23
$0.00
Revenue trend · last 6Q
—
—
-100%
—
—
-42%
Q4 21
Q4 22
Q4 23
Q3 24
Q4 24
Q1 26
$0
$106.1K
-$1
$0
$0
$62.0K
Margins · last 6Q
Gross
—
Profit
-2095.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How GELS stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related